ACIP convened on December 1, 2020, in advance of the completion of FDA’s review of the Emergency Use Authorization application, to provide interim guidance to federal, state, and local jurisdictions on allocation of initial doses of COVID-19 vaccine.

ACIP recommended that, when a COVID-19 vaccine is authorized by FDA and recommended by ACIP, both 1) health care personnel and 2) residents of long-term care facilities be offered vaccination in the initial phase of the COVID-19 vaccination program (Phase 1a).

The interim recommendation might be updated over the coming weeks based on additional safety and efficacy data from phase III clinical trials and conditions of FDA Emergency Use Authorization.
• Health care personnel are defined as paid and unpaid persons serving in health care settings who have the potential for direct or indirect exposure to patients or infectious materials.

• LTCF residents are defined as adults who reside in facilities that provide a range of services, including medical and personal care, to persons who are unable to live independently.
Policy Question

- Should vaccination with Pfizer-BioNTech COVID-19 vaccine (2-doses, IM) be recommended for persons 16 years of age and older under an emergency use authorization?

https://www.cdc.gov/mmwr/volumes/69/wr/mm6950e2.htm?s_cid=mm6950e2_w
https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/covid-19.html
Interim Clinical Considerations for Use of Pfizer-BioNTech COVID-19 Vaccine

On December 12, 2020, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use of the Pfizer-BioNTech COVID-19 vaccine for the prevention of COVID-19 in persons aged 16 years and older. The Pfizer-BioNTech COVID-19 vaccine is a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine encoding the prefusion spike glycoprotein of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19).

These CDC clinical considerations are informed by data submitted to the Food and Drug Administration for Emergency Use Authorization (EUA) of the vaccine, other data sources, general best practice guidelines for immunization, and expert opinion. In addition to the following considerations, the EUA conditions of use and storage, handling, and administration procedures described in the prescribing information should be referenced when using the Pfizer-BioNTech COVID-19 vaccine.

Administration

The Pfizer-BioNTech COVID-19 vaccine series consists of two doses (30 μg, 0.3 ml each) administered intramuscularly, three weeks apart. Doses administered within a grace period of 4 days (i.e., between days 17 and 21) are considered valid however, if the second dose is administered earlier than day 17, it does not need to be repeated. If more than 21 days have elapsed since the first dose, the second dose should be given at the earliest opportunity; the series does not need to be repeated.

Interchangeability with other COVID-19 vaccine products

The Pfizer-BioNTech COVID-19 vaccine is not interchangeable with other COVID-19 vaccine products and efficacy of a mixed-product series have not been evaluated. Persons initiating vaccination with Pfizer-BioNTech vaccine should complete the series with this product. If two doses of different mRNA COVID-19 vaccine products are inadvertently administered, no additional doses of either product are recommended at this time. Recommendations may be updated as further information becomes available or other vaccine types (e.g., viral vector, protein subunit vaccines) are authorized.

- Training opportunities, webinars, toolkits announced/released
  

- COVID-19 vaccination website for healthcare professionals

- Pfizer-BioNTech COVID-19 Vaccine webpage


- COVID-19 vaccine information for consumers

- CDC COVID-19 Vaccination Provider Agreement at COVID-19 Vaccination Provider Requirements and Support | CDC